報價延遲最少15分鐘:2024/12/24 13:26 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.76/-0.64
|
|
企業價值
67.93M
|
| 資產負債 |
|
每股賬面淨值
-0.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:26 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. |